NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
61
Data completeness
5/8 — Partial
Priority Review
VENCLEXTA (venetoclax) by AbbVie is p-glycoprotein inhibitors [moa]. First approved in 2016.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENCLEXTA (venetoclax) is an oral BCL-2 inhibitor approved in 2016 that works by blocking anti-apoptotic proteins to induce cancer cell death. It is used primarily in hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The drug functions as a P-glycoprotein inhibitor, allowing malignant cells to undergo programmed cell death.
$0.815BPart D
Peak7.2 years to LOEVENCLEXTA is at peak commercial maturity with $815M in Part D spending (2023), indicating a large, established field infrastructure and stable commercial team.
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
BCL-2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (61)
The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations
Started Nov 2026
30 enrolled
Myeloid Tumors
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
Started Nov 2026
450 enrolled
Acute Myeloid Leukaemia (AML)Acute Myeloid Leukaemia
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Started Aug 2026
32 enrolled
Acute Myeloid LeukemiaTP53 Gene Mutation
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Started Jul 2026
660 enrolled
Acute Myeloid Leukemia
Worked on VENCLEXTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.